Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Terminated
Axcan Pharma
Phase 3
2009-11-30
This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group
comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories
(MAX-002) as compared to placebo and active medicine after 6 weeks of treatment in adults
with mild to moderate ulcerative proctitis (UP).
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Terminated
Forest Laboratories
Phase 3
2009-11-30
This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group
comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories
(MAX-002) as compared to placebo and active medicine after 6 weeks of treatment in adults
with mild to moderate ulcerative proctitis (UP).
An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Establish
Therapeutic Equivalence of 1000 mg Mesalamine Rectal Suppositories and Canasa® Rectal
Suppositories (1000 mg Mesalamine, USP) in the Treatment of Mild to Moderate Ulcerative
Proctitis will be conducted in 533 patient with a estimated duration of 18months.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
